Citigroup reduced its price objective for ProKidney, with stock changes and ratings reported by Benzinga and MarketBeat.
1 report, 1 independent
Updated Oct 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup reduced its price objective for ProKidney, with stock changes and ratings reported by Benzinga and MarketBeat.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
Related events
- Seadrill received a target price increase report from Benzinga, while Citigroup reaffirmed a neutral rating and MarketBeat provided average ratings.
- Citigroup lowered its stock rating for Smiths Group, while MarketBeat provided average rating data for the company.
- Citigroup raised its price objective for Waters Corporation stock, with the research note reported by Benzinga.
- MarketBeat provided average rating data for the stock, and Citigroup began coverage on Whitehawk Therapeutics shares.
- Affirm received analyst rating updates from Susquehanna and Citigroup, with Benzinga reporting the changes.